Operations
Protherics employs approximately 300 employees across its operations in the UK, US and Australia.
Research and Development
Our R&D operation is managed from the UK with support from our US offices in Brentwood, Tennessee, where our main regulatory group is based and Salt Lake City, Utah.
Sales and Marketing and Corporate
Our sales and marketing operations are managed from our US office in Brentwood, Tennessee and our Corporate office in London, England.
| Corporate Office, EU |
|
Brentwood Office, US |
| Protherics PLC |
|
Protherics Inc |
| 3 Creed Court |
|
5214 Maryland Way |
| 5 Ludgate Hill |
|
Suite 405 |
| London |
|
Brentwood |
| EC4M 7AA |
|
Tennessee 37027 |
| UK |
|
USA |
Contact: David Briscoe
+44 (0)20 7246 9950 |
|
Contact: Saul Komisar
+1 615 327 1027 |
Manufacturing
Our main manufacturing facilities are located in Wales, where we undertake the commercial production of our polyclonal antibody products, CroFab™, DigiFab™ and ViperaTAb™, and the manufacture of CytoFab™ for clinical development. Additional manufacturing facilities are located near Adelaide, South Australia where we raise the polyclonal antibodies used in these products. We also have a facility in Salt Lake City where we manufacture OncoGel™.
All of our commercial product manufacturing facilities meet FDA (US), MHRA (UK), TGA (Australia) and current Good Manufacturing Practice (cGMP) requirements for the manufacture of biopharmaceuticals. The facility in Wales has also been awarded an Investigational Medicinal Products (IMP) manufacturers authorisation by the MHRA for a range of operations.